Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism.
Satoko KawarasakiHonami SawazakiHiroaki IijimaSu-Ping NgJungin KwonShinsuke MohriMari IwaseHuei-Fen JhengHaruya TakahashiWataru NomuraKazuo InoueTeruo KawadaTsuyoshi GotoPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2020)
Canagliflozin prevented body weight gain through the suppression of lipid synthesis via both dosing methods, although there were some differences in the efficacy. The findings of our study can help to identify new mechanisms of action of SGLT2 inhibitors and potential applications.